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A novel method was developed to assemble a full-length infectious cDNA of the group II coronavirus mouse
hepatitis virus strain A59 (MHV-A59). Seven contiguous cDNA clones that spanned the 31.5-kb MHV genome
were isolated. The ends of the cDNAs were engineered with unique junctions and assembled with only the
adjacent cDNA subclones, resulting in an intact MHV-A59 cDNA construct of 31.5 kb in length. The
interconnecting restriction site junctions that are located at the ends of each cDNA are systematically removed
during the assembly of the complete full-length cDNA product, allowing reassembly without the introduction
of nucleotide changes. RNA transcripts derived from the full-length MHV-A59 construct were infectious,
although transfection frequencies were enhanced 10- to 15-fold in the presence of transcripts encoding the
nucleocapsid protein N. Plaque-purified virus derived from the infectious construct replicated efficiently and
displayed similar growth kinetics, plaque morphology, and cytopathology in murine cells as did wild-type
MHV-A59. Molecularly cloned viruses recognized the MHV receptor (MHVR) for docking and entry, and
pretreatment of cells with monoclonal antibodies against MHVR blocked virus entry and replication. Cells
infected with molecularly cloned MHV-A59 virus expressed replicase (gene 1) proteins identical to those of
laboratory MHV-A59. Importantly, the molecularly cloned viruses contained three marker mutations that had
been derived from the engineered component clones. Full-length infectious constructs of MHV-A59 will permit
genetic modifications of the entire coronavirus genome, particularly in the replicase gene. The method has the
potential to be used to construct viral, microbial, or eukaryotic genomes approaching several million base pairs
in length and used to insert restriction sites at any given nucleotide in a microbial genome.
The Nidovirales order includes mammalian and avian posi-
tive-polarity, single-stranded RNA viruses in the arterivirus
and coronavirus families (43). The Coronaviridae family is fur-
ther subdivided into the Coronavirus and Torovirus genera (14,
45). Despite remarkable size differences in the genomic RNA
(13 to 32 kb), the polycistronic genome organization and reg-
ulation of gene expression from a nested set of subgenomic
mRNAs are similar for all members of the order (29, 45).
Coronaviruses contain the largest single-stranded, plus-polar-
ity RNA genome in nature, ranging in size from about 27 to 31
kb in length, and are divided into three subgroups based upon
antigenic and sequence comparisons (29, 43). The group I
coronaviruses include human coronavirus strain 229E (HCV
229E) and transmissible gastroenteritis virus (TGEV). The
group II coronaviruses contain mouse hepatitis virus (MHV),
bovine coronavirus, and HCV OC43. Bovine coronavirus is an
important pathogen of cattle while HCV infection is associated
with a significant percentage of common colds in winter. The
group III coronaviruses contain infectious bronchitis virus (IBV).
The MHV-A59 and MHV-JHM strains are the most exten-
sively studied group II coronaviruses, and infection in suscep-
tible mice results in a panencephalitis with acute and chronic
demyelination that is histologically similar to multiple sclerosis
in humans (28). MHV-A59 is also hepatotropic, and infection
results in hepatitis (30). The MHV-A59 virion contains a
31.5-kb genome that encodes 10 large open reading frames
(ORFs) (8). The genomic RNA is packaged by a 50-kDa nu-
cleocapsid protein (N) into a helical nucleocapsid structure
and acquires an envelope by budding into intermediate com-
partments between the endoplasmic reticulum and the Golgi
complex (18, 37, 38, 50). The MHV virion contains three or
four virus proteins including a spike glycoprotein of 180/90
kDa (S), a 65-kDa hemagglutinin esterase (HE), a 23-kDa
membrane glycoprotein (M), and an 11-kDa E protein (33,
34, 53). Note that the HE glycoprotein is encoded as a pseu-
dogene in some MHV strains, including MHV-A59 (34, 51).
Consequently, its function in MHV replication and pathogen-
esis is not clear. Much of our knowledge concerning the rep-
lication strategy of coronaviruses has focused on the use of
MHV as a model for pathogenesis, docking and entry, receptor
usage, transcription, replication, polymerase function, and as-
sembly and release (4, 5, 6, 9, 10, 12, 15, 21, 22, 23, 40, 41, 42,
54).
The MHV-A59 gene 1 (replicase gene) is about 22 kb in
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length and contains two large overlapping ORFs (1a and 1b)
with 1b in the 1 reading frame with respect to ORF1a (8, 12).
ORF1b expression requires a ribosomal frameshift at a
pseudoknot structure in the 1a-1b overlap region (12). Thus,
the replicase gene is capable of expressing two large polypro-
teins, the ORF1a polyprotein (pp1a, 495 kDa) and the 1a/ab
fusion polyprotein (pp1ab, 803 kDa) (8, 12, 25). ORF1a en-
codes at least three experimentally confirmed protease activi-
ties including two papain-like proteases (PLP1 and PLP2) and
a polio 3C-like protease (3CLpro) (9, 20, 31, 32,). Neither pp1a
nor pp1ab is detected intact in MHV-infected cells since the
proteinases process the polyproteins cotranslationally and
posttranslationally into at least 14 mature replicase proteins (9,
10, 19, 20, 31, 32). The PLP1 cleavage products include the p28
and p65 proteins, both of which are derived from the N ter-
minus of ORF1a (20). The 3CLpro cleavage products include
MP1, 3CLpro, p10, p22, p12, and p15, all of which are
derived from the C terminus of pp1a (10). ORF1b is cleaved by
3CLpro into at least four mature products, including putative
polymerase and helicase polypeptides (19). The functions of
most of the replicase proteins in MHV-A59 replication and
pathogenesis are unknown, although genetic complementation
analysis with temperature-sensitive mutations suggests at least
eight distinct functions that influence RNA synthesis (46).
Many of the replicase proteins are associated with membranes
that are also sites of viral RNA synthesis (19, 44).
Molecular genetic analysis of the structure and function of
RNA virus genomes has been profoundly advanced by the
availability of full-length cDNA clones, from which infectious
RNA transcripts can be derived that replicate efficiently when
introduced into permissive cell lines (1, 2, 11). Until recently,
the large size of the coronavirus RNA genome, coupled with
regions of chromosomal instability, hindered the development
of full-length infectious cDNAs. To circumvent these prob-
lems, a novel targeted recombination-based approach was de-
veloped, which involved the use of a molecularly cloned defec-
tive-interfering-like RNA and took advantage of high RNA
recombination frequencies during mixed MHV infection (26,
27, 35). Targeted recombination has been very useful for stud-
ies of the 3-most 9 kb of the MHV genome but has not been
used for other regions of the genome, notably the replicase
gene (26, 27).
Two general strategies have recently been developed to as-
semble full-length infectious cDNAs of coronavirus RNA ge-
nomes. One strategy involved the stable cloning of full-length
group I coronaviruses (TGEV and HCV 229E) cDNAs into
bacterial artificial chromosomes or vaccinia virus (3, 48). Then,
molecularly cloned recombinant virus was recovered following
either a DNA- or an RNA-based launch, respectively. A full-
length infectious cDNA of IBV has also been assembled in
vaccinia virus vectors (13). In contrast to these approaches, we
have assembled a full-length infectious cDNA of TGEV by in
vitro ligation from six component subclones and the subse-
quent in vitro transcription of infectious RNAs (52). In this
system, each of the component clones terminates in a restric-
tion site that leaves a variable 3- or 4-nucleotide end, gener-
ated by a BglI or BstXI site, respectively. The different ends
target assembly with only the appropriate adjacent subclones.
A strength of this system is that reverse genetic applications
are simplified in the component clones compared with the
sequence complexity of full-length cDNAs. This allows for
rapid reverse genetic applications within individual segments
of the viral genome as well as the ability to rapidly mix and
match mutations in different regions of the genome (17, 52).
In this study we describe a full-length cDNA of MHV-A59,
the first group II coronavirus that has been successfully recov-
ered from a genome-length reverse genetic system. The assem-
bly of full-length cDNAs of the group II coronaviruses has
been hampered by the presence of numerous toxic regions in
the viral ORF1 polymerase, which are unstable in bacteria with
high- or low-copy-number plasmid vectors. We have solved this
problem by using a strategy that separates the toxic regions
during cloning and then regenerates the exact wild-type MHV
sequence at the junctions between the component clones. This
vector will allow for detailed reverse genetic applications
throughout the entire MHV genome and will serve as a model
for the assembly of other group II coronavirus full-length
cDNAs, as well as other RNA and DNA viruses and microbial
genomes.
MATERIALS AND METHODS
Cells and viruses. Delayed brain tumor (DBT) cells were originally established
from a CDF1 mouse inoculated intracerebrally with the Schmidt-Ruppin strain
of Rous sarcoma virus. DBT cells were maintained in Eagle’s minimum essential
medium supplemented with 10% fetal clone II, 5% tryptose phosphate broth,
0.05 g of gentamicin/ml, and 0.25 g of kanamycin/ml. DBT-9 cells were
FIG. 1. Strategy to assemble an infectious cDNA of MHV-A59. (A) Esp3I cloning properties. In the traditional mode, an Esp3I site resides at
the 3 end of the MHV A subclone and upon cleavage results in a novel 4-nucleotide overhang which will specifically anneal with the
complementary 4-nucleotide overhang generated by an identical Esp3I site located at the 5 end of the MHV B fragment. Note that the MHV
wild-type sequence is re-formed intact and the Esp3I site is retained in the virus sequence. However, the Esp3I recognition site is a nonpalindromic
sequence, and as such, a simple flip in orientation allows for the specific removal of the Esp3I recognition site in the MHV A and B subclones,
leaving 4-nucleotide complementary overhangs, which re-form the intact wild-type sequence upon ligation. No evidence of the Esp3I site that has
been engineered into the component clones should remain in the assembled product (No See’m technology). In this cartoon, the sequences
represent wild-type MHV sequence but are not the exact nucleotides encoded at the MHV A/B junction (Tables 1 and 2). (B) Component clones
used in the assembly of a full-length MHV-A59 cDNA. The MHV genome is a linear positive-polarity RNA of about 31,500 nucleotides in length.
By using RT-PCR and unique oligonucleotide primer mutagenesis, seven clones spanning the entire MHV genome were isolated by standard
recombinant DNA techniques. Unique Esp3I and BglI sites, located at the junctions between each of the cDNA clones, were used to assemble a
full-length infectious cDNA. A unique T7 start site was inserted at the 5 end of clone A, and a 25-nucleotide T tail and downstream SfiI site were
encoded at the 3 end of clone G. The approximate location of each site is shown. (C) Location of the MHV component clone junctions. MHV
ORF1a and ORF1b polyproteins are proteolytically processed into numerous smaller proteins, which presumably function to direct virus
replication and transcription. The component clone A/B, B/C, C/D, D/E, and E/F junctions are shown relative to the ORF1 polyproteins
synthesized during MHV-A59 infection. The F/G junction resides in the HE glycoprotein pseudogene. utr, untranslated region; nt, nucleotide.
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isolated from DBT cells by fluorescence-activated cell sorting with a monoclonal
antibody directed against the MHV receptor (MHVR) (15, 23). Consequently,
these cells express a relatively uniform and abundant amount of MHVR, the
receptor for MHV-A59 docking and entry into cells (15, 16). Baby hamster
kidney (BHK) cells were kindly provided by Robert E. Johnston (University of
North Carolina at Chapel Hill) and maintained in alpha minimum essential
medium supplemented with 10% fetal calf serum, 10% tryptose phosphate broth,
0.05 g of gentamicin/ml, and 0.25 g of kanamycin/ml. Plasmid encoding the
MHVR (Bgp1a) and monoclonal antibodies against the murine MHVR were
kindly provided by K. Holmes, University of Colorado Health Sciences Center.
BHK cells transfected with the MHVR were subjected to fluorescence-activated
cell sorting twice with monoclonal antibody CC1 and maintained in alpha min-
imum essential medium containing 10% fetal calf serum, 10% tryptose phos-
phate broth, 0.05 g of gentamicin/ml, 0.25 g of kanamycin/ml, and 800 g of
Geneticin (G418 sulfate; Sigma)/ml.
The MHV-A59 strain of MHV was used throughout the course of these
experiments. Our wild-type MHV-A59 was obtained from Larry Sturman and
had been plaque purified three times through L2 cells maintained at 40°C.
MHV-A59 and molecularly cloned viruses were plaque purified in DBT cells,
and stocks were grown in DBT cells.
Blockade experiments. DBT or BHK-MHVR cells were seeded at densities of
2  105 into four-chambered LabTek slides overnight and then incubated with
100 l of a 1:4 dilution of anti-MHVR monoclonal antibody CC1 for 45 min at
room temperature. The CC1 monoclonal antibody was collected from hybridoma
culture supernatants and binds to the N-terminal domain of MHVR (23). After
incubation, the antibodies were removed and the cells were challenged with
MHV-A59 or molecularly cloned viruses at a multiplicity of infection (MOI) of
10 for 1 h at room temperature. The virus inoculates were then removed, the
cultures were washed twice with phosphate-buffered saline (PBS) to remove
residual virus, and 750 l of complete medium containing a 1:16 dilution of CC1
was added to the cultures. Virus samples were harvested at different times
postinfection and stored at 70°C for plaque assay in DBT-9 cells (15).
Mutagenesis, cloning, and sequencing of the MHV-A59 genome. The cloning
strategy for a full-length MHV-A59 construct is illustrated in Fig. 1 and is based
upon the observation that the Esp3I restriction endonuclease cleaves at a specific
nonpalindromic sequence and leaves highly variable 4-nucleotide ends that will
not randomly self-assemble. Rather, these DNAs will anneal only with fragments
containing the complementary 4-nucleotide overhang generated at identical
Esp3I sites. The MHV-A59 genome was cloned from infected DBT cell intra-
cellular RNA by reverse transcription-PCR (RT-PCR) with primer pairs di-
rected against conserved regions in MHV-A59 and MHV-JHM (Tables 1 and 2).
To create unique junction sites for assembly of a full-length MHV-A59 cDNA
construct, primer-mediated PCR mutagenesis was used to insert unique Esp3I
restriction sites at the 5 and 3 ends of each subclone (Table 2) (Fig. 1). These
primer pairs did not alter the coding sequence and resulted in RT-PCR ampli-
cons ranging in size from 1.4 to 8.6 kb in length. Briefly, total intracellular RNA
was isolated from MHV-A59-infected cells with Trizol reagent according to the
manufacturer’s directions (Invitrogen). To isolate the MHV-A59 subclones, re-
verse transcription was performed with Superscript II and oligodeoxynucleotide
primers according to the manufacturer’s recommendations (Gibco BRL). For
sequence comparisons and primer design, we used the MHV-A59 sequence as
reported in GenBank (30). Following cDNA synthesis at 50°C for 1 h, the cDNA
was denatured for 2 min at 94°C and amplified by PCR with Expand Long TAQ
polymerase (Boehringer Mannheim Biochemical) for 25 cycles of 94°C for 30 s,
58°C for 25 to 30 s, and 68°C for 1 to 7 min depending upon the size of the
amplicon. The PCR amplicons were isolated from agarose gels and cloned into
Topo II TA (Invitrogen), pGem-TA cloning (Promega), or pSMART (Lucigen)
vectors according to the manufacturer’s directions.
Three to seven independent clones of each MHV-A59 amplicon were isolated
and sequenced by using a panel of insert-specific primers and an ABI model
automated sequencer. A consensus sequence for each of the cloned fragments
was determined, and a consensus clone was assembled by using restriction en-
zymes and standard recombinant DNA techniques.
Assembly of a full-length MHV-A59 infectious construct (icMHV-A59). Each
of the plasmids was grown to a high concentration, isolated, and digested, or
double digested, with Esp3I, BglI, or NotI according to the manufacturer’s di-
rections (New England Biolabs) (Fig. 1A). The MHV-A59 A clone was digested
with MluI, which is located in the Topo II plasmid, treated with calf intestine
alkaline phosphatase, and subsequently digested with Esp3I. The MHV-A59 G
clone was SfiI digested, treated with calf alkaline phosphatase, and then Esp3I
digested. All other vectors were digested with Esp3I or Esp3I/BglI. The appro-
priately sized cDNA inserts were visualized in 0.8 to 1.2% agarose gels in TAE
buffer (Tris-acetate-EDTA) with Darkreader technology (Claire Chemical Re-
search, Denver, Colo.) and isolated with Qiaex II gel extraction kits (Qiagen Inc.,
Valencia, Calif.). Darkreader technology allows DNA visualization under visible
light and does not cause DNA damage. Appropriate cDNA subsets (AB,
CDE, and FG) were pooled into 100- to 200-l aliquots, and equivalent
amounts of each DNA were ligated with T4 DNA ligase (15 U/100 l) at 16°C
TABLE 1. Design of the MHV-A59 junction sequencesa
MHV-A59 subclone Restriction site junction Location Junction
A 54TCGTTAA2CAAATGAGACGNNNN-3 3-end A fragment, Esp3I, nt 4882 A/B
34AGCAATTGTTT1ACTCTGCNNNN-5
B 5-NNNNCGTCTCA2CAAATTTGAT33 5-end B fragment, Esp3I, nt 4883 A/B
3-NNNNGCAGAGTGTTT1AAACTA35
54CTTTGCCT2TAACGGCGAGTTC-3 3-end B fragment, BglI, nt 9555 B/C
34GAAACGGAATT1GCCGCTCAAG-5
C 5-CTTTGCCT2TAACGGCGAGTTC33 5-end C fragment, BglI, nt 9556 B/C
3-GAAACGGAATT1GCCGCTCAAG35
54TAGCATA2AACCAGAGACGNNNN-3 3-end C fragment, Esp3I, nt 11510 C/D
34ATCGTATTTGG1TCTCTGCNNNN-5
D 5-NNNNCGTCTCA2AACCACGACGTC33 5-end D fragment, Esp3I, nt 11511 C/D
3-NNNNGCAGAGTTTGG1TGCTGCAG35
54TATGCTAT2CCTAAGAGACGNNNN-3 3-end D fragment, Esp3I, nt 12961 D/E
34ATACGATAGGAT1TCTCTGCNNNN-5
E 5-NNNNCGTCTCT2CCTAAGTGACTG33 5-end E fragment, Esp3I, nt 12962 D/E
3-NNNNGCAGAGAGGAT1TCACTGAC35
54ACTCTAAT2GTCTAGAGACGNNNN-3 3-end E fragment, Esp3I, nt 15754 E/F
34TGAGATTACAGA1TCTCTGCNNNN-5
F 5-NNNNCGTCTCT2GTCTATCGTGCG33 5-end F fragment, Esp3I, nt 15755 E/F
3-NNNNGCAGAGACAGA1TAGCACGC35
54ACAGTCGG2TCCGAGAGACGNNNN-3 3-end F fragment, Esp3I, nt 22739 F/G
34GTCAGCCAGGC1TCTCTGCNNNN-5
G 5-NNNNCGTCTCG2TCCGACTGTACC33 5-end G fragment, Esp3I, nt 22740 F/G
3-NNNNGCAGAGCAGGC1TGACATGG35
a Horizontal arrows indicate the direction of the MHV coding sequences in an individual clone, vertical arrows indicate the site of restriction, and an underline
represents the resulting 3- or 4-nucleotide overhang generated at each junction. Various restriction sites are shown in boldface. N, any nucleotide can be inserted at
this position. The 3 end of MHV G is as described for pMH54 (27). nt, nucleotide.
11068 YOUNT ET AL. J. VIROL.
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overnight in 30 mM Tris-HCl (pH 7.8)–10 mM MgCl2–10 mM dithiothreitol–1
mM ATP. Appropriately sized products (A/BC/D/E and F/G) were separated
in 0.7% agarose gels as described above, isolated, and religated as described
above. The final products were purified by phenol-chloroform-isoamyl alcohol
(1:1:24) and chloroform extraction and precipitated under ethanol prior to in
vitro transcription reactions. The full-length MHV-A59 construct is designated
MHV-A59 1000. Alternatively, the seven MHV cDNA fragments were isolated,
pooled, and simultaneously ligated in real time at 4°C for 18 h with T4 DNA
ligase. The DNA products were phenol-chloroform extracted, precipitated, and
resuspended in H2O.
N gene transcripts may enhance coronavirus transfection efficiencies (13, 52).
To provide transcripts encoding N in trans, the MHV-A59 N gene was amplified
from the MHV G clone with primer pairs flanking the N gene ORF. The
upstream primer contained an SP6 site (5-TCGGCCTCGATGGCCATTTAG
GTGACACTATAGATGTCTTTTGTTCCTGGGCAAG-3) [a59Sp6Ng()]
while the downstream primer introduced a 26-nucleotide oligo(T) stretch pro-
viding a poly(A) tail following in vitro transcription [5-TCCGGA(TTT)8-TTA
CACATTAGAGTCATCTTCTAACC-3] [A59Ng3()]. The MHV-A59
leader RNA sequence and the 3 noncoding sequences were not present within
this construct.
RNA transfection. Full-length transcripts of the MHV-A59 1000 cDNA con-
struct were generated in vitro as described by the manufacturer (Ambion, Austin,
Tex; mMessage mMachine) with certain modifications. For 2 h at 37°C, reactions
were performed with 30-l reaction mixtures that were supplemented with 4.5 l
of a 30 mM GTP stock, resulting in a 1:1 ratio of GTP to cap analog. Similar
reactions were performed with reaction mixtures with 1 g of PCR amplicons
carrying the MHV-A59 N gene sequence or Sindbis virus noncytopathic repli-
cons encoding green fluorescent protein and a 2:1 ratio of cap analog to GTP (1).
The transcripts were treated with DNase I, denatured, and separated in 0.5%
agarose gels in TAE buffer containing 0.1% sodium dodecyl sulfate (SDS).
Alternatively, the transcripts were either treated with 5 ng of RNase A for 15 min
at room temperature, treated with DNase I, or directly electroporated into BHK
or BHK-MHVR cells. Briefly, BHK and DBT cells were grown to subconfluence,
trypsinized, washed twice with PBS, and resuspended in PBS at a concentration
of 107 cells/ml. RNA transcripts were added to 800 l of the BHK cell suspension
in an electroporation cuvette, and three electrical pulses of 850 V at 25 F were
given with a Bio-Rad Gene Pulser II electroporator. The transfected BHK cells
were seeded with 1.0  106 to 2.0  106 uninfected DBT cells in a 75-cm2 flask
and incubated at 37°C for 2 days. Virus progeny were then passaged in DBT cells
at 18-h intervals and twice purified by plaque assay. Alternatively, BHK-
MHVR cells were electroporated with RNA transcripts as described above, and
virus cytopathology and fusion were evident within 30 h posttransfection.
Replicase gene protein expression. Replicase gene protein expression was
determined as previously described (10, 19, 20, 31, 32). Briefly, monolayers of
DBT cells were infected with wild-type MHV-A59 or plaque-purified molecu-
larly cloned viruses at an MOI of 10 PFU/cell at 37°C. At 5.5 h postinfection
(p.i.), 5 g of actinomycin D/ml was added to the overlying medium. At 6 h p.i.,
200 Ci of [35S]Met/ml was added to the culture medium, and the cells were
harvested at 8 h p.i. Cells were harvested by being washed in 10 mM Tris HCl
(pH 7.4), followed by lysis in buffer containing 10 mM Tris HCl (pH 7.4), 2%
SDS, 1% NP-40, and 1% sodium deoxycholate. The lysates of whole cells were
adjusted to 1% SDS and immunoprecipitated with antibodies directed against
the mature ORF1a proteins p28 and p65 (UP102) (20) or against MP1 (MP1),
p10 (p10), p22 (p22), p12 (p12), and p15 (p15) (10). Immunoprecipitated
proteins were isolated with protein A-Sepharose beads and separated on SDS–5
to 18% gradient polyacrylamide gels. Proteins were visualized and prepared with
Adobe Photoshop 5.0.
Marker mutations and sequence analysis. In contrast with the design of the
TGEV infectious cDNA, the MHV-A59 construct used Esp3I sites that were lost
during assembly of the final full-length MHV-A59 cDNA (Fig. 1). Consequently,
marker mutations associated with the assembly of the full-length MHV-A59 1000
construct included changes in the three Esp3I sites (positions 3518, 4875, and
17138) that were removed from the wild-type virus sequence during the con-
struction of the MHV A and F subclones and the presence of an RsrII site in the
HE pseudogene in the pMH54 construct (MHV G clone, position 22750) (27).
Briefly, intracellular RNA was isolated from MHV-A59- or molecularly cloned
virus-infected cells and used as a template for RT-PCR with primer pairs that
spanned nucleotides 2020 to 5031, 16351 to 17875, or 22060 to 25416. Following
RT-PCR, the amplicons were isolated from 0.8% agarose gels. Two aliquots
were diluted into the appropriate restriction buffer and incubated at 37°C in the
presence or absence of either Esp3I or RsrII as described by the manufacturer
(NEN). The products were separated in 0.8% agarose gels in TAE, visualized,
and photographed. The remainder of the sample was cloned into Topo II TA
cloning vectors as described by the manufacturer (Invitrogen), and the appro-
priate subclones were sequenced with an ABI automated sequencer.
RESULTS
Theoretical considerations. We have previously assembled a
full-length cDNA of TGEV from which in vitro transcripts
resulted in infectious virus (17, 52). Six cDNAs were isolated
that spanned the entire TGEV genome, and each clone was
engineered with a unique flanking interconnecting junction,
which could assemble with only the adjacent cDNA subclones,
resulting in an intact TGEV cDNA construct of 28.5 kb in
length. The interconnecting junctions were formed by using a
subclass of restriction enzymes (e.g., BglI-GCCNNNN2NG
GC) that recognize a palindrome sequence but leave 64 (43)
different variable ends that will assemble only with the appro-
priate 3-nucleotide complementary overhang generated at an
identical BglI site (Fig. 1). As such, several unique BglI restric-
tion sites were introduced into the TGEV sequence to allow
for the assembly of a full-length cDNA.
We reasoned that this systematic assembly approach could
be readily applied to other coronaviruses including MHV
(MHV-A59), and our strategy is shown in Fig. 1. The MHV-
A59 genome contains several regions of sequence toxicity-
instability, which map between 10 and 15 kb in the MHV
ORF1a/ORF1b polyprotein, and a second region mapping
around 5.0 kb in ORF1a (data not shown). More stable cDNAs
can be isolated if the toxicity-instability domain is precisely
divided into two independent subclones (52). With MHV,
identification of appropriate junctions to stabilize specific
cDNA clones required extensive PCR amplification and clon-
ing and eventually confined some junctions to within a domain
of a few hundred base pairs. MHV-A59 sequence constraints
precluded the insertion of BglI, BstXI, or a related restriction
site within these narrow boundaries; therefore, a variation of
this approach was used to assemble a full-length cDNA of
MHV-A59.
We used a novel approach to build the unique interconnect-
ing junctions between the MHV-A59 cDNAs that has broad
and largely unappreciated molecular biology applications. The
strategy is based on the unique properties associated with the
restriction enzyme Esp3I. Like BstXI, Esp3I is a nontraditional
restriction enzyme that leaves a 4-nucleotide variable end, re-
sulting in 256 unique potential ends. However, in contrast with
these enzymes, Esp3I does not cleave within a palindromic
sequence (5-CGTCTCN2NNNN-3) but rather recognizes a
strand-specific site that can be used in traditional and “No
See’m” cloning strategies (Fig. 1A) (No See’m sites are named
after a very small biting insect that is occasionally found on
North Carolina beaches). With traditional approaches, Esp3I
sites can be oriented to re-form the recognition site in recom-
binant viruses following in vitro ligation of two adjacent MHV
cDNAs. However, a simple reverse orientation places both
Esp3I sites at the ends of the viral cDNAs, with the variable
overhang generated from the virus sequence. Upon cleavage
and ligation with the adjoining fragment, both Esp3I sites are
lost from the final product, leaving the exact MHV-A59 se-
quence at the junction. Restriction enzymes encoding similar
properties include SapI, BsaI, and BsmI and others (39).
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Assembly of a full-length infectious cDNA of MHV-A59. We
reasoned that these enzymatic properties would allow for the
assembly of a full-length MHV-A59 cDNA with minimal se-
quence alteration at the junctions between component clones.
As the wild-type MHV-A59 genome contained three Esp3I
sites, silent mutations were inserted to disrupt these sites
around nucleotide positions 3518 and 4875 in MHV A and
position 17138 in the MHV F cDNA fragment. Breaking the
sequence at nucleotides 4882, 11510, 12961, and 15754 re-
duced the toxicity-instability domains in the MHV-A59
cDNAs. Consequently, seven MHV-A59 cDNAs that con-
tained unique Esp3I or BglI interconnecting junctions were
isolated by using specific primer pairs and RT-PCR (Fig. 1B).
The introduced Esp3I sites did not alter the amino acid se-
quence because they were eliminated during the assembly of
the full-length genomic cDNA (Table 1). The MHV-A59 A
cassette (4.9 kb) contained a T7 RNA polymerase start at the
5 end and terminated in an Esp3I site located at position 4882.
The resulting 4-nucleotide CAAA overhang formed the MHV
A/B junction. The MHV-A59 B fragment (4.6 kb) contained
the same Esp3I site at its 5 end and terminated in a natural
BglI site located at position 9555 in the MHV-A59 genome.
The resulting 3-nucleotide TAA overhang formed the basis of
the unique B/C junction. The MHV-A59 C fragment (2.0 kb)
encoded the BglI site at the 5 end and terminated in an Esp3I
site at position 11510. The resulting AACC sequence formed
the basis for the MHV C/D junction. The MHV-A59 D frag-
ment (1.5 kb) encoded the position 11510 Esp3I site and
terminated in an Esp3I site that was engineered at position
12961. To prevent spurious assembly with other fragments, we
engineered in a CCTA sequence (wild-type sequence is
ACTT) that formed the basis for the MHV D/E interconnect-
ing junction. This did not change the protein sequence of
MHV-A59. The MHV-A59 E fragment (2.8 kb) terminated
in an Esp3I site at position 15754 with the resulting GTCT
sequence serving as the E/F junction (Fig. 1C). The MHV F
cDNA clone (7.0 kb) terminated in an Esp3I site located in
the HE glycoprotein gene at position 22739 and left a TCCG
junction (27, 30). This included the introduction of a T-to-C
alteration at position 22742. The MHV-A59 G fragment (8.7
kb) was derived from the pMH54 construct used in targeted
recombination (kindly provided by Paul Masters). For our
purposes, pMH54 was modified by introducing an Esp3I site at
nucleotide 22740 partially overlapping with an RsrII site that is
present in the pMH54 construct (Table 1). The MHV F and G
cDNAs can be assembled with either the Esp3I or RsrII sites.
Primer pairs used to introduce these restriction sites and form
the unique interconnecting junctions are shown in Table 2.
Using RT-PCR and the primer pairs shown in Table 2, we
successfully isolated stable clones that spanned the MHV ge-
nome. Importantly, the clones encoding the toxic domains
(MHV B, C, and D) were most stable at 30°C in pSMART
vectors. Three to seven independent clones of each were se-
quenced, and a consensus cDNA clone was established for
each of the MHV A, B, C, D, E, and G cDNAs by standard
recombinant DNA techniques. The final consensus sequence
in our construct contained two amino acid changes from the
published sequence, a T-to-C change at position 5304 (Ser-
Pro) and an A-to-T change at position 6796 (Lys-Met) (30).
To assemble a full-length cDNA of the MHV genome, plas-
mids were digested and the appropriate-sized inserts were iso-
lated from agarose gels (Fig. 2A). Two assembly strategies
were devised. In the first approach, the MHV A and B; C, D,
and E; and F and G fragments were ligated overnight in the
FIG. 2. Assembly of an MHV-A59 full-length cDNA. (A) Plasmid
DNAs were restricted with the appropriate enzymes and separated in
0.8% agarose gels, and the MHV cDNAs were purified from gels. The
sizes (in kilobases) of the MHV fragments are as follows: A, 4.8; B,
4.3; C, 2.0; D, 1.5; E, 2.8; F, 7.0; and G, 8.7. DNA molec-
ular size markers flank the MHV cDNAs. (B) The purified cDNAs
were pooled and incubated with T4 DNA ligase for 12 h at 4°C.
One-thirtieth of the assembled products were separated in 0.5% aga-
rose gels overnight at 15 V. Lane 1, small-molecular-size 1-kb markers;
lane 2, in vitro transcripts derived from MHV-A59 1000 and treated
with DNase I; lane 3, high-molecular-weight markers; lane 4, shotgun-
assembled MHV-A59 component cDNAs. The arrow indicates the
presence of large-molecular-size 31.5-kb cDNA.
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presence of T7 DNA ligase. The ligation products were iso-
lated from agarose gels, and the MHV A/B, C/D/E, and F/G
fragments were pooled and ligated overnight. The final prod-
ucts were purified by phenol-chloroform-isoamyl alcohol ex-
traction and precipitated under ethanol, and an aliquot was
separated in agarose gels (data not shown). In the second
approach, purified MHV A, B, C, D, E, F, and G fragments
were pooled and ligated overnight at 4°C. The products were
phenol-chloroform extracted and concentrated by precipita-
tion (Fig. 2B). In both approaches, an appropriately sized
full-length MHV-A59 cDNA of approximately 31.5 kb in
length (MHV-A59 1000) was generated as well as some assem-
bly intermediates, especially evident during simultaneous liga-
tion. Capped T7 transcripts were synthesized, treated with
DNase, and analyzed in 0.5% agarose gels (Fig. 2B). Low
levels of high-molecular-weight transcript were evident follow-
ing T7 transcription of ligated fragments in vitro. DNase treat-
ment removed the MHV-A59 full-length cDNA as well as the
incomplete assembly intermediates (data not shown).
Transfection and recovery of infectious virus. BHK cells are
nonpermissive for MHV-A59 infection because of a block in
virus docking and entry. However, BHK cells were used be-
cause of high transfection efficiencies with infectious corona-
virus genomic RNAs (48, 52). As previous studies with TGEV
and IBV have demonstrated that N transcripts may enhance
transfection efficiencies of genome-length transcripts (13, 52),
we included MHV N transcripts in our initial transfection
studies. As BHK cells will function as single-hit hosts, the
transfected BHK cells were seeded into 75-cm2 flasks contain-
ing 1.0  106 to 2.0  106 DBT cells, which are permissive for
MHV replication. By 36 h, cytopathology was evident in the
transfected cultures. When the media from these cultures were
passaged into a fresh flask of DBT cells, viral cytopathology
was evident by 12 h p.i., and molecularly cloned virus produced
plaques in DBT cells and reached high titers of 107 PFU/ml.
No infectious virus or cytopathology was evident from MHV-
A59 1000 DNA-transfected cultures or from RNase A-treated
transcripts (data not shown). Several plaques were isolated
from these passage 1 cultures. Titers of molecularly cloned
virus stocks were determined at 0.9  108 to 2.0  108 PFU/ml
(icMHV-A59#1, icMHV-A59#2, icMHV-A59#3, icMHV-
A59#4, and icMHV-A59#5) and had similar plaque morphol-
ogy as did wild-type virus (Fig. 3).
BHK-MHVR cells express the receptor for MHV-A59 dock-
ing and entry into cells and are susceptible to infection (15, 16).
Consequently, transfection of MHV-A59 1000 transcripts into
BHK-MHVR cells allows for additional rounds of progeny
virion multiplication. To determine if MHV-A59 N transcripts
enhanced the infectivity of full-length transcripts, cultures of
BHK-MHVR cells were transfected in the presence or absence
of N transcripts, and the cultures were fixed at 16 and 25 h p.i.
By fluorescent antibody staining, cotransfected cultures dis-
played significantly increased amounts of viral antigen at 16
and 25 h p.i. compared with cultures transfected with MHV-
A59 1000 transcripts alone (Fig. 4). Viral antigen expression
was noted within regions of viral cytopathology and fusion
indicative of S glycoprotein expression. Consonant with these
findings, virus titers at 25 h p.i. were 1.9  104 and 2.8  105
PFU/ml in the absence or presence of N transcripts, respec-
tively. These data indicate that N transcripts are not necessary
for infectivity of MHV-A59 1000 transcripts, although infec-
tivity is enhanced 10- to 15-fold.
Phenotype of molecularly cloned viruses. Cultures of DBT
cells were infected with wild-type MHV-A59 and several mo-
lecularly cloned viruses at an MOI of 10 for 1 h at room
temperature, and virus samples were harvested at the indicated
times. Wild-type and molecularly cloned viruses had indistin-
guishable growth characteristics in DBT cells and reached ti-
ters of 2.0  108 PFU/ml within 16 h p.i. (Fig. 5). Wild-type
MHV-A59 infection in DBT cells is sensitive to blockade with
monoclonal antibody CC1, which binds the N-terminal domain
of MHVR (23). As shown in Fig. 5A, both wild-type MHV-
A59 and molecularly cloned viruses were sensitive to CC1
blockade, consistent with the notion that MHVR was being
recognized as a receptor for docking and entry into DBT cells.
To further test this hypothesis, BHK-MHVR cells were pre-
treated with CC1 monoclonal antibodies and then infected
with wild-type MHV-A59 or various molecularly cloned viruses
(Fig. 5B). MHV-A59 and the molecularly cloned viruses could
not replicate in BHK cells unless the MHVR receptor was
expressed and present on the surface of cells (Fig. 5C). More-
over, pretreatment of BHK-MHVR cells with CC1 blocked the
replication of both wild-type MHV-A59 and the molecularly
cloned viruses (Fig. 5B). These data indicate that the molecularly
cloned viruses used MHVR as a receptor for docking and entry.
FIG. 3. Molecularly cloned virus plaque morphology. Cultures of
BHK cells were electroporated with MHV-A59 1000 full-length tran-
scripts or MHV-A59 1000 cDNA and seeded with DBT cells in 75-cm2
flasks. Virus progeny were purified by plaque assay, and virus stocks
were grown as described in Materials and Methods. The figure shows
the plaque morphologies of wild-type MHV-A59 virus (A) and molec-
ularly cloned icMHV-A59#1 (B) and icMHV-A59#2 (C) virus.
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MHV replicase protein expression. Reverse genetic ap-
proaches are needed to determine the function of the gene 1
replicase proteins in coronavirus replication and pathogenesis.
Consequently, we compared the processing, mobility, and ex-
pression of the ORF1a replicase proteins in cultures of DBT
cells that had been infected with wild-type MHV-A59 or ic-
MHV-A59 at an MOI of 10. The cultures were radiolabeled
with [35S]methionine from 6 to 8 h p.i. Whole-cell lysates of
infected cells were immunoprecipitated with antisera directed
against previously characterized MHV-A59 ORF1a replicase
proteins (Fig. 6). The amino-terminal ORF1a proteins p28 and
p65 were detected in similar amounts and mobilities in ic-
MHV-A59 and wild-type virus. Further analysis of icMHV-
A59 demonstrated that the mature ORF1a replicase proteins
MP1, p12, p22, p10, and p15 were identical in amount and
mobility to those in wild-type-virus-infected cells. These data
also indicated that the proteinases responsible for these pro-
tein cleavages, PLP1, PLP2, and 3CLpro, functioned normally
in the molecularly cloned viruses. Thus, viruses recovered from
the genome-length cDNA were capable of normal replicase
protein processing and expression.
Identification of marker mutations in molecularly cloned
viruses. Molecularly cloned viruses should contain wild-type
sequence at most of the junctions but will have lost the three
Esp3I sites that were removed from the MHV-A59 A and G
fragments (positions 3518, 4875, and 17138). In addition, mo-
lecularly cloned viruses should carry an RsrII site in the HE
glycoprotein pseudogene that was present in the original
pMH54 construct (position 22750). Consequently, wild-type
MHV-A59 and various molecularly cloned viruses were inoc-
ulated into DBT cells, and intracellular RNA was isolated at
6 h p.i. With RT-PCR, several amplicons were generated that
spanned either the A/B and G/F junctions or the marker mu-
tations used to eliminate the naturally occurring Esp3I sites in
the MHV genome (Fig. 7). Results of restriction fragment
length polymorphism analysis demonstrated that the three ex-
pected Esp3I sites, but not the RsrII site, were present in the
wild-type MHV-A59 genome (Fig. 7). In contrast, molecularly
cloned MHV-A59 virus contained the unique marker muta-
tions that had eliminated these three Esp3I restriction sites in
the MHV-A59 1000 full-length cDNA (Fig. 7). Importantly,
molecularly cloned viruses contained the expected RsrII site
that was present in the MHV G fragment and contained wild-
type sequence at each of the Esp3I junctions used to assemble
the full-length cDNA (Fig. 7 and 8). The appropriate PCR
products were subcloned and sequenced, demonstrating that
the appropriate mutations were present in the viruses isolated
from the infectious construct (Fig. 8). Clearly, MHV-A59 1000
transcripts were infectious and produced virus which contained
not only the appropriate marker mutations but also wild-type
virus sequence at each of the junctions.
FIG. 4. Viral antigen expression in the presence or absence of nucleocapsid transcripts. Cultures of BHK-MHVR cells were electroporated with
MHV-A59 1000 alone or with a mixture of MHV-A59 1000 and N gene transcripts as described in Materials and Methods. In LabTek chambers,
2  105 cells were seeded and fixed at 16 and 25 h posttransfection. With murine antiserum against MHV-A59, fluorescent antibody staining
demonstrated that MHV-A59 1000 transcripts were infectious in the presence or absence of N transcripts. (A B) Untransfected culture at 16 h;
(B) untransfected culture at 25 h; (C) culture transfected in the absence of N transcripts, at 16 h; (C) culture transfected in the presence of N
transcripts, at 16 h; (E) culture transfected in the absence of N transcripts, at 25 h (F) culture transfected in the presence of N transcripts, at 25 h.
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In this study we report the first reverse genetic system for a
group II coronavirus, MHV-A59, which allows for the success-
ful recovery of infectious virus following assembly of a ge-
nome-length cDNA from a series of contiguous cDNA sub-
clones. The approach was similar to the strategy that was used
to assemble a full-length infectious cDNA of TGEV except
that it was not usually necessary to introduce mutations and
new restriction sites into the wild-type virus genome to direct
the assembly cascade (52). Rather, we have demonstrated that
type IIS restriction endonuclease Esp3I sites can be used to
create the unique interconnecting junctions and yet be subse-
quently removed from the final assembly product, allowing for
the reconstruction of an intact wild-type sequence. This ap-
proach avoided the introduction of nucleotide changes that are
normally associated with building a full-length cDNA product
of a viral genome. These nonpalindromic restriction sites will
also provide other novel recombinant DNA applications. For
example, by PCR, it will be possible to insert Esp3I or a related
nonpalindromic restriction site at any given nucleotide in a
viral genome and use the variable domain for simple and rapid
site-specific mutagenesis. By orienting the restriction sites as
No See’m, the sites are removed during reassembly, leaving
only the desired mutation in the final DNA product. The dual
properties of strand specificity and a variable end overhang
that can be tailored to match any sequence allow for Esp3I
sites to be engineered as universal connectors that can be
joined with any other 4-nucleotide restriction site overhang
(e.g., EcoRI, PstXI, and BamHI). Alternatively, No See’m sites
can be used to insert foreign genes into viral, eukaryotic, or
microbial genomes or vectors, simultaneously removing all ev-
FIG. 5. Growth curves of molecularly cloned and wild-type MHV-
A59. Cultures of 2.0  105 DBT, BHK, or BHK-MHVR cells were
infected with various molecularly cloned viruses and wild-type MHV-
A59 at an MOI of 10 for 1 h. In some instances prior to infection, the
cells had been pretreated with a 1:2 dilution of monoclonal antibody
CC1, directed against the MHVR. Virus samples were taken at the
indicated times. The figure shows virus growth in DBT (A), BHK-
MHVR (B), and BHK (C) cells, respectively.
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idence of the restriction sites that were used in the recombi-
nant DNA manipulation.
The MHV-A59 systematic assembly strategy involves seven
contiguous cDNAs and offers several unique advantages as a
reverse genetic system for coronaviruses. These include (i)
reduced sequence complexity and the corresponding increased
availability of rare restriction sites that allow for rapid reverse
genetic manipulations in individual cassettes compared with a
full-length genome clone; (ii) sequence compartmentalization
in individual cassettes, minimizing the possibility of spurious
second-site mutations and recombination that may occur fre-
quently in large inserts during recombinant DNA manipula-
tions; (iii) the disruption of the MHV toxic regions, which are
normally unstable in microbial vectors; (iv) avoidance of the
introduction of mutations that create new restriction sites in
the viral sequence; (v) compatibility with vaccinia virus or
bacterial artificial chromosome vectors; and (vi) the fact that
the theoretical limits of the assembly cascade with the rarest
cutters like SapI greatly exceed the sizes of most million-base-
pair microbial genomes as well as all RNA and DNA viral
genomes described to date. As such, many DNA and RNA
virus and microbial genomes could also be reassembled from
component clones by this approach.
We purposely introduced several silent changes to remove
preexisting Esp3I sites that resided within the MHV-A59 ge-
nome sequence and to distinguish between molecularly cloned
and wild-type viruses. In one instance, the Esp3I site at position
4875 was removed because it left a TTAA overhang that would
have prevented the directionality of assembly. The other Esp3I
sites were removed to minimize the total number of MHV-A59
subclones used in the assembly cascade. In two instances, we
inserted silent mutations into the Esp3I overhang to maximize
sequence specificity and directionality at a particular junction
(Tables 1 and 2), but this could be circumvented by choosing
slightly different junction sites. The MHV cDNA cassettes can
be ligated systematically as described for TGEV or simulta-
neously. Although numerous incomplete assembly intermedi-
ates were evident, our demonstration that simultaneous liga-
tion of seven cDNAs will result in full-length cDNA will
FIG. 6. Expression of replicase proteins of wild-type MHV-A59
and icMHV-A59. Wild-type MHV-A59 and icMHV-A59#1 were in-
oculated onto monolayers of DBT cells at an MOI of 10 for 1 h. Cells
were maintained for 5.5 h in Dulbecco modified Eagle medium–2%
fetal calf serum, and at 5.5 h, the media were replaced with Dulbecco
modified Eagle medium that lacked methionine and cysteine and con-
tained 2% fetal calf serum. Actinomycin D (2 g/ml) was also added at
5.5 h p.i., and at 6.0 h, the cultures were pulsed with [35S]Met for 2 h.
Cells were lysed at 8 h p.i. in lysis buffer containing 10 mM Tris-HCl,
1% NP-40, and 2% SDS. Immunoprecipitation of replicase proteins
was performed in 200-l reaction mixtures containing lysate from
105 cells in 10 mM Tris–1% NP-40–1% SDS. The specificities and
sensitivities of the antibodies directed against p28/p65 (UP102), MP1
(MP1), 3CLpro (B3), p12 (p1a-12), p22 (p22), p10 (p1a-10), and
p15 (p1a-15) have been reported previously (10, 19, 20, 31, 32).
Molecular weight markers are shown to the left of each gel, and black
circles identify the various MHV replicase protein products.
FIG. 7. Restriction fragment length polymorphism analysis of molecularly cloned virus. Cultures were infected with MHV-A59 or icMHV-A59#1,
and intracellular RNA was isolated at 8 h p.i. With primer pairs and RT-PCR, cDNA amplicons were isolated that contained the various marker
mutations that had been inserted into the component clones. The purified wild-type MHV-A59 and icMHV-A59#1 amplicons were restricted with Esp3I
or RsrII and separated in 0.8% agarose gels. Lane 1, wild-type A59 amplicon from nucleotides 2020 to 5031, uncut; lane 2, wild-type A59 amplicon from
nucleotides 2020 to 5031 digested with Esp3I; lane 3, icMHV-A59#1 amplicon from nucleotides 2020 to 5031, uncut; lane 4, icMHV-A59#1 amplicon
from nucleotides 2020 to 5031, Esp3I digested; lane 5, wild-type A59 amplicon from nucleotides 16351 to 17875, uncut; lane 6, wild-type A59 amplicon
from nucleotides 16351 to 17875 restricted with Esp3I; lane 7, icMHV-A59#1 amplicon from nucleotides 16351 to 17875, uncut; lane 8, icMHV-A59#1
amplicon from nucleotides 16351 to 17875 restricted with Esp3I; lane 9, wild-type A59 amplicon from nucleotides 22060 to 25416, uncut; lane 10, wild-type
A59 amplicon from nucleotides 22060 to 25416 restricted with RsrII; lane 11, icMHV-A59#1 amplicon from nucleotides 22060 to 25416, uncut; lane 12,
icMHV-A59#1 amplicon from nucleotides 22060 to 25416 restricted with RsrII; lane 13, 1-kb ladder.
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simplify the complexity of the assembly strategy. At this time,
there is no evidence to indicate that this approach might in-
troduce spurious mutations or genome rearrangements from
aberrant assembly cascades. However, it is possible that such
variants might arise following RNA transfection, as a conse-
quence of high-frequency MHV RNA recombination between
incomplete and genome-length transcripts (35). It is likely that
such variants would be replication impaired and rapidly out-
competed by wild-type virus. A second limitation is that the
yield of full-length cDNA product is reduced, resulting in less
robust transfection efficiencies than those of the more tradi-
tional systematic assembly method.
The group I and III coronaviruses appear to encode a single
toxicity-instability region in ORF1a (3, 52). In contrast, MHV-
A59 contains several regions in ORF1, particularly between
nucleotides 9555 and 15754, that are highly unstable and/or
toxic in many high- or low-copy-number plasmids in Esche-
richia coli. To solve this problem, we took advantage of the
observation that toxicity can be significantly reduced if the
domains are bisected into two distinct subclones and if the
microbial vectors are propagated at 30°C. In MHV-A59, the
toxic regions map within the small 3CLpro cleavage products
at the C terminus of ORF1a, near the PLP about 5.0 kb in
ORF1a, and at the N terminus of ORF1b (10, 19, 20, 25, 31,
32). Instability appears to be associated with expression, as this
entire domain (nucleotides 9555 to 15754) is stable in yeast
vectors (pYES2.1 Topo TA cloning kit from Invitrogen) that
maintain tight regulation over foreign gene expression (B.
Yount et al., unpublished data). Importantly, the MHV B, C,
and D clones were most stable in low-copy-number pSMART
plasmids, which are transcription- and translation-free cloning
vectors. These vectors lack a -galactosidase promoter, and the
MHV inserts are flanked by strong transcriptional stops, pro-
viding further support for the hypothesis that toxicity is expres-
sion linked. We are determining if the entire C-to-E domain
can be stably cloned into pSMART vectors. As an alternative,
preliminary data also suggest that the MHV B, C, and D
inserts may be more stable in Topo II/pGEM vectors in the
presence of glucose, presumably from the induction of catab-
olite repression.
Coronaviruses have been demonstrated elsewhere to pack-
age low concentrations of subgenomic mRNAs, especially N
transcripts, and several studies have suggested that N tran-
scripts may function in transcription and replication and are
tightly associated with the replication complex (7, 19, 42, 47).
Previous studies in our laboratory with TGEV, and then in
other laboratories with IBV, have shown that N transcripts
enhance the infectivity of transcripts derived from coronavirus
full-length cDNAs (13, 52). With IBV, but not TGEV or HCV
229E, N transcripts are absolutely essential for full-length tran-
script infectivity (13). In this study, N transcripts enhanced the
infectivity of full-length MHV-A59 transcripts by 10- to 15-fold
as evidenced by increased viral antigen expression and virus
titers at 25 h p.i. It is unclear whether MHV N transcripts, N
protein, or both are essential for increased virus yields follow-
ing electroporation or whether this effect would be observed
with transcripts of unrelated genes. Previous reports indicate
that N transcripts do not appear absolutely necessary for HCV
229E subgenomic RNA transcription (49). Additional studies
are needed to determine exactly how N transcripts enhance
infectivity of coronavirus genome-length transcripts in vitro.
MHV-A59 has long served as a model system for studying
coronavirus genetics, polymerase function, replication, tran-
scription, receptor usage, assembly and release, and pathogen-
FIG. 8. Identification of marker mutations in recombinant virus.
Various icMHV-A59#1 or wild-type virus amplicons were subcloned
into Topo II vectors and sequenced. (A) icMHV-A59#1 sequence
across the mutated 3512 Esp3I site; (B) icMHV-A59#1 sequence
across the mutated 48 Esp3I site and the MHV A/B junction;
(C) icMHV-A59#1 sequence across the mutated 17 Esp3I site; (D) ic-
MHV-A59#1 sequence across the RsrII site and MHV F/G junction;
(E) wild-type MHV-A59 sequence across the same domain as shown in
panel D. Overlined sequences include the mutated restriction sites and
the corresponding wild-type nucleotides at these positions. In panels B
and D, the bracketed sequences represent the MHV A/B and F/G
junction domains, respectively. Note that all evidence of the Esp3I site,
which had been engineered into the sequence, is gone.
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esis (29). The availability of a full-length infectious cDNA of
MHV-A59 will allow for reverse genetic applications through-
out the entire MHV genome. Virus recovered from the infec-
tious construct replicated as efficiently as did wild-type virus,
approached titers of 108 PFU/ml within 16 h p.i., and, impor-
tantly, contained the marker mutations engineered into several
of the component clones. Molecularly cloned virus utilized
MHVR as a receptor for docking and entry into cells, was
sensitive to blockade with monoclonal antibodies against
MHVR, and displayed similar host range restriction as did the
wild-type virus. Consequently, the reverse genetic system will
prove applicable to studying MHV-A59 receptor interactions
as well as elucidating the mechanisms of coronavirus host
range expansion and persistence (5, 6, 15, 21, 22, 23, 41).
Further, the use of a cassette approach to construct infec-
tious cDNAs of MHV-A59 will allow for the precise and rapid
introduction of mutations into regions of the genome that are
currently inaccessible by targeted RNA recombination ap-
proaches, specifically the entire 5 two-thirds of the genome
and notably the MHV replicase gene, gene 1. Although a great
deal has been learned concerning the expression, processing,
targeting, and interactions of replicase gene proteins, it has not
been possible to determine the functions of most of them.
Novel functions that must be encoded include proteins that
regulate MHV discontinuous transcription, high-frequency
RNA recombination, and positive- and negative-strand RNA
synthesis. As arteriviruses use a similar transcriptional strategy
and yet encode a replicase gene that is one-third to one-half
the size of the MHV gene, it seems likely that novel nidovirus
gene 1 functions will be encoded in the coronavirus replicase
gene that assist in the replication of large RNA genomes. The
approaches described here will allow direct reverse genetic
studies of individual replicase gene proteins, as well as any
combination of proteins because of the ability to mix and
match different mutated gene fragments.
In summary, we have established a reverse genetic system
for the group II coronavirus MHV-A59. The strategy used in
the assembly of this infectious cDNA could be applied to other
important group II coronaviruses like bovine coronavirus, an
important pathogen of cattle, and HCV OC43, which is an
important cause of upper respiratory tract infections in hu-
mans. Moreover, it will be possible to target MHV to multiple
species by simple replacement of the S glycoprotein gene (27),
allowing for the development of MHV-A59 as a vaccine vector
in domesticated animals and humans. Host range variants of
MHV may recognize human CEA genes for docking and entry,
allowing for virus targeting of unique cell populations in hu-
mans (5, 6, 36). These features, coupled with a transcriptional
strategy that will likely allow for regulated expression of mul-
tiple genes from the genome, should allow for the use of
coronaviruses as heterologous vaccine vectors in humans and
animals (17, 24).
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